StemCyte International
Publicly listed on the Taipei Exchange (TPEX: 4178). A regenerative therapeutics company advancing FDA-licensed cord blood-derived cell therapies.
Corporate Overview
StemCyte operates across cord blood banking and regenerative cell therapy development, with primary operations in the United States and Taiwan. Founded in 1997 in California, the company holds both FACT and AABB accreditation and operates an FDA-licensed cGMP manufacturing facility in Baldwin Park, California. In 2024, StemCyte received FDA biologics license approval for REGENECYTE® (HPC, Cord Blood), BLA 125764/0, and received Regenerative Medicine Advanced Therapy (RMAT) designation for the Long COVID indication.
Regulatory & Corporate Milestones
Executive Team
30+ years in pharmaceutical research and business development. Previously VP Consumer Products Research at Johnson & Johnson and Director of Drug Delivery Technology at Bristol-Myers Squibb. Joined StemCyte in 2009.
View profileCareer began at Harvard Medical School under Judah Folkman. Led antibody drug development programs in Taiwan, including advancing R&D, governance, and IPO initiatives across multiple biotech startups.
View profileProfessor Emeritus at City of Hope. Over 25 years at the NCI-designated comprehensive cancer center, including more than a decade as Director of Pediatric Hematology-Oncology. Expert in bone marrow transplantation and umbilical cord blood therapy.
View profileAwards & Industry Standing
2025 Taiwan BIO Award for Innovation of the Year
Honored at the Presidential Office (Taiwan), 2025
Ranked 6th among Deloitte's top 50 fastest-growing technology companies in the Los Angeles area
Commissioned by U.S. HRSA to support the National Cord Blood Inventory (NCBI)
Investor & partner inquiries
For investor relations, partnership opportunities, or corporate inquiries.
Contact our team